14. Clinical benefit table: Fermathron. Continuous outcome measures.
Study | Time | Treatment | Outcome | N of Pts | Baseline Mean | End of Study Mean | Absolute Benefit | Relative Difference |
McDonald 2000 | 1‐4 wk | E: Fermathron | Lequesne Index (0‐24) | 114 | 11.21 | 7.92 | 0.37 (W) | 3.3% (W) |
C: Hyalart | 119 | 11.12 | 7.46 | |||||
McDonald 2000 | 5‐13 wk | E: Fermathron | Lequesne Index (0‐24) | 114 | 11.21 | 6.91 | 0.46 (W) | 4.1% (W) |
C: Hyalart | 119 | 11.12 | 6.36 | |||||
McDonald 2000 | 1‐4 wk | E: Fermathron | Pain (0‐100 mm VAS) | 114 | 56.2 | 31.3 | 3.3 (W) | 5.8% (W) |
C: Hyalart | 119 | 57.2 | 29.0 | |||||
McDonald 2000 | 5‐13 wk | E: Fermathron | Pain (0‐100 mm VAS) | 114 | 56.2 | 25.4 | 1.8 (W) | 3.1% (W) |
C: Hyalart | 119 | 57.2 | 24.6 |